Martrat, G;
Maxwell, CM;
Tominaga, E;
Porta-de-la-Riva, M;
Bonifaci, N;
Gómez-Baldó, L;
Bogliolo, M;
Lázaro, C;
Blanco, I;
Brunet, J;
et al.
Martrat, G; Maxwell, CM; Tominaga, E; Porta-de-la-Riva, M; Bonifaci, N; Gómez-Baldó, L; Bogliolo, M; Lázaro, C; Blanco, I; Brunet, J; Aguilar, H; Fernández-Rodríguez, J; Seal, S; Renwick, A; Rahman, N; Kühl, J; Neveling, K; Schindler, D; Ramírez, MJ; Castellà, M; Hernández, G; EMBRACE; Easton, DF; Peock, S; Cook, M; Oliver, CT; Frost, D; Platte, R; Evans, DG; Lalloo, F; Eeles, R; Izatt, L; Chu, C; Davidson, R; Ong, KR; Cook, J; Douglas, F; Hodgson, S; Brewer, C; Morrison, PJ; Porteous, M; Peterlongo, P; Manoukian, S; Peissel, B; Zaffaroni, D; Roversi, G; Barile, M; Viel, A; Pasini, B; Ottini, L; Putignano, AL; Savarese, A; Bernard, L; Radice, P; Healey, S; Spurdle, A; Chen, X; Beesley, J; kConFab; Rookus, MA; Verhoef, S; Tilanus-Linthorst, MA; Vreeswijk, MP; Asperen, CJ; Bodmer, D; Ausems, MG; van Os, TA; Blok, MJ; Meijers-Heijboer, HE; Hogervorst, FB; HEBON; Goldgar, DE; Buys, S; John, EM; Miron, A; Southey, M; Daly, MB; BCFR; SWE-BRCA; Harbst, K; Borg, A; Rantala, J; Barbany-Bustinza, G; Ehrencrona, H; Stenmark-Askmalm, M; Kaufman, B; Laitman, Y; Milgrom, R; Friedman, E; Domchek, SM; Nathanson, KL; Rebbeck, TR; Johannsson, OT; Couch, FJ; Wang, X; Fredericksen, Z; Cuadras, D; Moreno, V; Pientka, FK; Depping, R; Caldés, T; Osorio, A; Benítez, J; Bueren, J; Heikkinen, T; Nevanlinna, H; Hamann, U; Torres, D; Caligo, MA; Godwin, AK; Imyanitov, EN; Janavicius, R; GEMO Study Collaborators; Sinilnikova, OM; Stoppa-Lyonnet, D; Mazoyer, S; Verny-Pierre, C; Castera, L; de Pauw, A; Bignon, YJ; Uhrhammer, N; Peyrat, JP; Vennin, P; Ferrer, SF; Collonge-Rame, MA; Mortemousque, I; McGuffog, L; Chenevix-Trench, G; Pereira-Smith, OM; Antoniou, AC; Cerón, J; Tominaga, K; Surrallés, J; Pujana, MA
(2011)
Exploring the link between MORF4L1 and risk of breast cancer.
BREAST CANCER RESEARCH, 13 (R40).
ISSN 1465-542X
https://doi.org/10.1186/bcr2862
SGUL Authors: Hodgson, Shirley Victoria
|
["document_typename_application/pdf; charset=binary" not defined]
Published Version
Download (1MB) | Preview |
Abstract
INTRODUCTION: Proteins encoded by Fanconi anemia (FA) and/or breast cancer (BrCa) susceptibility genes cooperate in a common DNA damage repair signaling pathway. To gain deeper insight into this pathway and its influence on cancer risk, we searched for novel components through protein physical interaction screens. METHODS: Protein physical interactions were screened using the yeast two-hybrid system. Co-affinity purifications and endogenous co-immunoprecipitation assays were performed to corroborate interactions. Biochemical and functional assays in human, mouse and Caenorhabditis elegans models were carried out to characterize pathway components. Thirteen FANCD2-monoubiquitinylation-positive FA cell lines excluded for genetic defects in the downstream pathway components and 300 familial BrCa patients negative for BRCA1/2 mutations were analyzed for genetic mutations. Common genetic variants were genotyped in 9,573 BRCA1/2 mutation carriers for associations with BrCa risk. RESULTS: A previously identified co-purifying protein with PALB2 was identified, MRG15 (MORF4L1 gene). Results in human, mouse and C. elegans models delineate molecular and functional relationships with BRCA2, PALB2, RAD51 and RPA1 that suggest a role for MRG15 in the repair of DNA double-strand breaks. Mrg15-deficient murine embryonic fibroblasts showed moderate sensitivity to γ-irradiation relative to controls and reduced formation of Rad51 nuclear foci. Examination of mutants of MRG15 and BRCA2 C. elegans orthologs revealed phenocopy by accumulation of RPA-1 (human RPA1) nuclear foci and aberrant chromosomal compactions in meiotic cells. However, no alterations or mutations were identified for MRG15/MORF4L1 in unclassified FA patients and BrCa familial cases. Finally, no significant associations between common MORF4L1 variants and BrCa risk for BRCA1 or BRCA2 mutation carriers were identified: rs7164529, Ptrend = 0.45 and 0.05, P2df = 0.51 and 0.14, respectively; and rs10519219, Ptrend = 0.92 and 0.72, P2df = 0.76 and 0.07, respectively. CONCLUSIONS: While the present study expands on the role of MRG15 in the control of genomic stability, weak associations cannot be ruled out for potential low-penetrance variants at MORF4L1 and BrCa risk among BRCA2 mutation carriers.
Statistics
Actions (login required)
Edit Item |